Open Orphan (LSE:ORPH) is a rapidly-growing pharmaceutical services company with a focus on rare and orphan drugs.
Following its reverse takeover of hVIVO earlier this year, it has also become a world-leader in the provision of virology and vaccine challenge study services and viral laboratory services.
In the video below, provided by piworld, executive chairman Cathal Friel talks through what the firm does, the long-term opportunity it presents for investors, and its ongoing support work for companies developing coronavirus vaccinations.
piworld provides content for investors, by investors.
The organisation aims to help private investors get closer to companies and their management and – in turn – make more informed investment decisions.
• Company results presentations
• Management interviews
• Company visits
• Enlightened educational investor videos with investors, opinion formers, and industry leaders